Grifols, S.A. (GRFS)
Healthcare · NMS
Price as at 1 Oct 2026, 01:24 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Grifols, S.A. trades at $7.31, which is 19% above the $5.95 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 34 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 10.8 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
GRFS dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.094 | 1 |
| 2025 | $0.173 | 1 |
| 2021 | $0.456 | 1 |
| 2020 | $0.201 | 1 |
| 2019 | $0.394 | 2 |
| 2018 | $0.479 | 2 |
| 2017 | $0.375 | 2 |
| 2016 | $0.350 | 2 |
| 2015 | $0.353 | 2 |
| 2014 | $0.300 | 2 |
| 2013 | $0.136 | 2 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
GRFS earnings and analyst estimates
Recommendation mix, 2 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Grifols, S.A.
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
GRFS passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
6 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$30.94M · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$18.74M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$806.7K · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$275.2K · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$182.6K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in GRFS
Trades in GRFS disclosed by members of Congress and executive-branch officials, latest first:
- Daniel Goldman · HouseSell · $1,001 - $15,000 · traded 31 Mar 2023 · disclosed 17 Apr 2023
- Daniel Goldman · HouseBuy · $1,001 - $15,000 · traded 27 Feb 2023 · disclosed 20 Mar 2023
- Greg Gianforte · HouseSell · $100,001 - $250,000 · traded 11 Nov 2019 · disclosed 23 Dec 2019
- Donna Shalala · HouseSell · $1,001 - $15,000 · traded 24 Jun 2019 · disclosed 27 Apr 2020
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
GRFS peers
The largest companies in the same industry (Drug Manufacturers - General), then in the same sector.
- LLY Eli Lilly and Company
- JNJ Johnson & Johnson
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- NVSEF Novartis AG
- AZN.L AstraZeneca PLC
- NVO Novo Nordisk A/S
- PFE Pfizer Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Grifols, S.A. (GRFS) undervalued?
Against our fair value estimate of $5.95, GRFS at $7.31 is 19% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own GRFS?
6 of the institutions we track reported a position in GRFS in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is GRFS's P/E ratio?
GRFS trades at 10.8 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Grifols, S.A. (GRFS) pay a dividend?
Yes. Grifols, S.A. yields 3.73% at the current share price. It has paid $0.094 per share over the trailing twelve months. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its GRFS data?
Fundamentals for GRFS come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:24 UTC and is delayed. Our data quality score for this company is 96/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for GRFS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.